ArticleThe Journal of investigative dermatology2009
FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Article in The Journal of investigative dermatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Guidelines on the use of extracorporeal photopheresis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2014Guideline
- Spatially Guided and Single Cell Tools to Map the Microenvironment in Cutaneous T-Cell Lymphoma.Cancers · 2023Review
- Review
- The Role of Tumor Microenvironment in the Pathogenesis of Sézary Syndrome.International journal of molecular sciences · 2022Review
- High Expression of IKZF2 in Malignant T Cells Promotes Disease Progression in Cutaneous T Cell Lymphoma.Acta dermato-venereologica · 2021Article
- Review
- Peripheral T cell lymphomas: from the bench to the clinic.Nature reviews. Cancer · 2020Review
- Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome.Blood cancer journal · 2020Article
- Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.Cancer immunology, immunotherapy : CII · 2018Article
- New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.Frontiers in oncology · 2018Review
- The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: The Treg role in skin diseases pathogenesis.Postepy dermatologii i alergologii · 2017Review
- T-cell lymphomas, a challenging disease: types, treatments, and future.International journal of clinical oncology · 2017Review
- TIGIT and Helios Are Highly Expressed on CD4The Journal of investigative dermatology · 2017Article
- A three-signal model of T-cell lymphoma pathogenesis.American journal of hematology · 2016Review
- Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.American journal of hematology · 2016Review
- [Update on extracorporeal photopheresis].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2015Review
- The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4(+) Foxp3(+) CD25(-) T cells in patients with leukemic cutaneous T-cell lymphoma.Photodermatology, photoimmunology & photomedicine · 2015Article
- Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous T-cell lymphoma (CTCL) has been suggested by in vitro experiments to represent a malignant CD4+ T-cell proliferation with a regulatory T-cell (Treg) phenotype (CD4+CD25+FOXP3+). We investigated percentages of FOXP3+ and CD25+ cells in the blood of 15 Sézary, 14 mycosis fungoides (MF), and 10 psoriasis (Pso) patients and 20 normal healthy donors (NHDs). We found similar numbers of FOXP3+ cells in MF (10.4% of blood CD4+ cells) and Pso (11.1%) patients and NHDs (9.8%). In 8 of 15 (53%) Sézary patients, significantly reduced percentages of FOXP3+ cells were seen in blood (2.9%) and skin (10.4%). Interestingly, 6 of 15 (40%) Sézary patients showed significantly increased percentages of FOXP3+ cells (39.7% (blood), 20.3% (skin)); however, these cells did not express CD25. In these latter patients, clone-specific TCR-Vbeta-chain antibodies were used to demonstrate that these FOXP3+CD25- cells were monoclonal CTCL tumor cells. FOXP3+CD25- CTCL tumor cells showed a highly demethylated status of the foxp3 gene locus similar to Treg cells, and they were functionally able to suppress IL-2 mRNA induction in TCR-stimulated conventional T cells. Thus, FOXP3+CD25- CTCL tumor cells with functional features of Treg cells define a subgroup of Sézary patients who might carry a different prognosis and might require differential treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.